The efficacy and safety of cannabidiol as adjunct treatment for drug-resistant idiopathic epilepsy in 51 dogs: A double-blinded crossover study
Journal of Veterinary Internal Medicine · 01.11.2023 · 37 (6) · 2291-2300
DOI: 10.1111/jvim.16912 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, online erschienen am 01.11.2023. Verfasst von Aaron J Rozental und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University Veterinary, Fort Collins, Colorado…. Hauptthemen laut MEDLINE: Cannabidiol, Dog Diseases. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: American Kennel Club Canine Health Foundation.
Abstract (Originalsprache)
Background
Approximately 30% of dogs with idiopathic epilepsy (IE) are drug-resistant. Recent studies have suggested cannabidiol (CBD) may be an effective anticonvulsant in dogs with IE.
Objective
To evaluate the addition of CBD to antiseizure drugs (ASDs) on seizure frequency and to report adverse events in dogs with drug-resistant IE. Animals Fifty-one dogs. Dogs having at least 2 seizures per month while receiving at least 1 ASD were included in the trial.
Methods
Double-blinded placebo-controlled crossover study. The 5 mg/kg/day dosage met futility requirements after 12 dogs, and a dosage of 9 mg/kg/day was used in the next 39 dogs. Dogs were randomly assigned to receive CBD or placebo for 3 months, with a 1-month washout period between oils. Total numbers of seizures and seizure days were recorded. Diagnostic testing was performed periodically throughout the trial.
Results
At the 9 mg/kg/day dose, the decrease in total seizure frequency was significant compared with placebo. A 24.1% decrease in seizure days occurred in dogs receiving CBD and a 5.8% increase occurred in dogs receiving placebo (P ≤ .05). No significant difference was found in the number of responders (≥50% decrease in total seizures or seizure days). Liver enzyme activities increased at both dosages. Decreased appetite and vomiting were more common in the CBD phase (P ≤ .05). Conclusions and Clinical Importance Cannabidiol decreased total seizures and seizure days compared to placebo when administered to dogs PO at 9 mg/kg/day. Liver enzymes should be monitored with administration of CBD in dogs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University Veterinary, Fort Collins, Colorado, USA.
ORCID-Profile: Isabella Corsato Alvarenga, Stephanie McGrath
Förderung
- American Kennel Club Canine Health Foundation
Zitieren
APA
Rozental, A. J., Weisbeck, B. G., Corsato Alvarenga, I., Gustafson, D. L., Kusick, B. R., Rao, S., Bartner, L. R., & McGrath, S. (2023). The efficacy and safety of cannabidiol as adjunct treatment for drug-resistant idiopathic epilepsy in 51 dogs: A double-blinded crossover study. Journal of Veterinary Internal Medicine, 37(6), 2291-2300. https://doi.org/10.1111/jvim.16912
Vancouver
Rozental AJ, Weisbeck BG, Corsato Alvarenga I, Gustafson DL, Kusick BR, Rao S, et al. The efficacy and safety of cannabidiol as adjunct treatment for drug-resistant idiopathic epilepsy in 51 dogs: A double-blinded crossover study. Journal of Veterinary Internal Medicine. 2023;37(6):2291-2300. doi:10.1111/jvim.16912
BibTeX
@article{Rozental2023,
author = {Rozental, Aaron J and Weisbeck, Brooke G and Corsato Alvarenga, Isabella and Gustafson, Daniel L and Kusick, Breonna R and Rao, Sangeeta and Bartner, Lisa R and McGrath, Stephanie},
title = {The efficacy and safety of cannabidiol as adjunct treatment for drug-resistant idiopathic epilepsy in 51 dogs: A double-blinded crossover study},
journal = {Journal of Veterinary Internal Medicine},
year = {2023},
volume = {37},
number = {6},
pages = {2291--2300},
doi = {10.1111/jvim.16912}
}
EUVIMED